These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 37816937)

  • 21. Systems analysis of human brain gene expression: mechanisms for HIV-associated neurocognitive impairment and common pathways with Alzheimer's disease.
    Levine AJ; Miller JA; Shapshak P; Gelman B; Singer EJ; Hinkin CH; Commins D; Morgello S; Grant I; Horvath S
    BMC Med Genomics; 2013 Feb; 6():4. PubMed ID: 23406646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV and Cognitive Impairment in Clinical Practice: The Evaluation of a Stepwise Screening Protocol in Relation to Clinical Outcomes and Management.
    Hakkers CS; Kraaijenhof JM; van Oers-Hazelzet EB; Visser-Meily AJMA; Hoepelman AIM; Arends JE; Barth RE
    AIDS Patient Care STDS; 2017 Sep; 31(9):363-369. PubMed ID: 28783374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Machine learning models reveal neurocognitive impairment type and prevalence are associated with distinct variables in HIV/AIDS.
    Tu W; Chen PA; Koenig N; Gomez D; Fujiwara E; Gill MJ; Kong L; Power C
    J Neurovirol; 2020 Feb; 26(1):41-51. PubMed ID: 31520320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic Risk Factors as Differential Predictors of Profiles of Neurocognitive Impairment Among Older HIV+ and HIV- Adults: An Observational Study.
    Pasipanodya EC; Montoya JL; Campbell LM; Hussain MA; Saloner R; Paolillo EM; Jeste DV; Letendre SL; McCutchan JA; Heaton RK; Moore DJ
    Arch Clin Neuropsychol; 2021 Feb; 36(2):151-164. PubMed ID: 31696212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of Molecular Properties of Antiretroviral Agents to Enhance CNS Penetration Abilities for the Treatment of Cognitive Impairment in HIV-Associated Neurocognitive Disorder.
    Danta CC; Piplani P
    ACS Chem Neurosci; 2020 Jul; 11(14):2034-2038. PubMed ID: 32573244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Machine Learning Approaches to Understand Cognitive Phenotypes in People With HIV.
    Mukerji SS; Petersen KJ; Pohl KM; Dastgheyb RM; Fox HS; Bilder RM; Brouillette MJ; Gross AL; Scott-Sheldon LAJ; Paul RH; Gabuzda D
    J Infect Dis; 2023 Mar; 227(Suppl 1):S48-S57. PubMed ID: 36930638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence, Demographic Correlates, and Medical Correlates of Cognitive Impairment Among Iranian People Living With HIV: A Cross-sectional Survey Study.
    Etesami MS; Jones DL; Sadeghi-Firoozabadi V; Abbasian L; Ghayomzadeh M; Mohraz M; Vance DE; Cysique LA; Asgarabad MH
    J Assoc Nurses AIDS Care; 2022 Jul-Aug 01; 33(4):421-435. PubMed ID: 35081086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV.
    Trunfio M; Rugge W; Mighetto L; Vai D; Atzori C; Nigra M; Domini S; Borgogno E; Guastamacchia G; Bonora S; Di Perri G; Calcagno A
    AIDS; 2020 Nov; 34(13):1899-1906. PubMed ID: 32701580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1-associated central nervous system dysfunction.
    Krebs FC; Ross H; McAllister J; Wigdahl B
    Adv Pharmacol; 2000; 49():315-85. PubMed ID: 11013768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV infection of the central nervous system: clinical features and neuropathogenesis.
    Boissé L; Gill MJ; Power C
    Neurol Clin; 2008 Aug; 26(3):799-819, x. PubMed ID: 18657727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuropathogenesis of HIV-1: insights from across the spectrum of acute through long-term treated infection.
    Killingsworth L; Spudich S
    Semin Immunopathol; 2022 Sep; 44(5):709-724. PubMed ID: 35882661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy.
    Guha D; Mukerji SS; Chettimada S; Misra V; Lorenz DR; Morgello S; Gabuzda D
    AIDS; 2019 Mar; 33(4):615-625. PubMed ID: 30557159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuropathogenesis of HIV and emerging therapeutic targets.
    Siddiqui A; He C; Lee G; Figueroa A; Slaughter A; Robinson-Papp J
    Expert Opin Ther Targets; 2022 Jul; 26(7):603-615. PubMed ID: 35815686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals.
    Ceccarelli G; Brenchley JM; Cavallari EN; Scheri GC; Fratino M; Pinacchio C; Schietroma I; Fard SN; Scagnolari C; Mezzaroma I; Vullo V; d'Ettorre G
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29160817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.
    Heaton RK; Franklin DR; Ellis RJ; McCutchan JA; Letendre SL; Leblanc S; Corkran SH; Duarte NA; Clifford DB; Woods SP; Collier AC; Marra CM; Morgello S; Mindt MR; Taylor MJ; Marcotte TD; Atkinson JH; Wolfson T; Gelman BB; McArthur JC; Simpson DM; Abramson I; Gamst A; Fennema-Notestine C; Jernigan TL; Wong J; Grant I; ;
    J Neurovirol; 2011 Feb; 17(1):3-16. PubMed ID: 21174240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
    Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
    J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of CNS Viral Seeding by HIV
    Veenstra M; León-Rivera R; Li M; Gama L; Clements JE; Berman JW
    mBio; 2017 Oct; 8(5):. PubMed ID: 29066542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive Impairment and Persistent CNS Injury in Treated HIV.
    Chan P; Hellmuth J; Spudich S; Valcour V
    Curr HIV/AIDS Rep; 2016 Aug; 13(4):209-17. PubMed ID: 27188299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.